Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
Request this program for your region or organization today! This live (online or in-person) presentation, and others like it, are available for free for Members. View our complete listing of presentations and programs by visiting our Custom Program Request page.
Request Program